17 Feb 2023

The approval of Ximluci® in Europe positions Xbrane as a leading global biosimilar developer

14 Feb 2023

Invitation to presentation of Xbrane Biopharma’s Year-end report 2022 on February 17, 2023.

17 Jan 2023

STADA and Xbrane obtain British approval for Ximluci® (ranibizumab) biosimilar referencing Lucentis®

15 Dec 2022

XBRANE PROVIDES AN UPDATE ON RANIBIZUMAB BIOSIMILAR CANDIDATE FDA FILING

11 Nov 2022

STADA and Xbrane secure EU approval for Ximluci® (ranibizumab) biosimilar referencing Lucentis®

31 Oct 2022

Change of number of shares and votes in Xbrane

28 Oct 2022

Presentation of Xbrane Biopharma’s interim report January – September 2022 on October 28, 2022

28 Oct 2022

Xbrane Biopharma releases interim report for January – September 2022

26 Oct 2022

Invitation to presentation of Xbrane Biopharma’s interim report January – September 2022 on October 28, 2022